US Patent

US8318682 — 1′substituted carba-nucleoside analogs for antiviral treatment

Composition of Matter · Assigned to Gilead Sciences Inc · Expires 2029-04-22 · 3y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of nucleoside compounds with a cyano group substitution at the 1' position, useful for treating Flaviviridae virus infections, particularly hepatitis C.

USPTO Abstract

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted with a cyano group. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Drugs covered by this patent

Patent Metadata

Patent number
US8318682
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-04-22
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.